Platelet-T cell aggregates in lung cancer patients: Implications for thrombosis
Fig 1
Platelet-leukocyte aggregates in lung cancer patients compared to healthy volunteers.
(A) Whole blood from healthy volunteers (white) or lung cancer patients (gray) was labeled with markers for leukocytes (anti-CD45), neutrophils (anti-CD66B), monocytes (anti-CD3 negative, anti-CD14+), natural killer cells (anti-CD56), CD4+ T cells (anti-CD4), CD8+ T cells (anti-CD8), or B cells (anti-CD19). Samples were co-labeled with APC-conjugated anti-CD42b. Mann Whitney nonparametric test. *** p ≤ 0.001.